Regenerative Medicine Market is anticipated to Touch USD 60.08 Bn by 2030

Latest Study on “Regenerative Medicine Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

The global Regenerative Medicine market size is expected to be worth around US$ 60.08 billion by 2030, according to a new report by Nova one advisor.

The global Regenerative Medicine market size was valued at US$ 27.85 billion in 2021 and is anticipated to grow at a CAGR of 14.27 % during forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6841

The emergence of gene therapy coupled with the developments in stem cell and tissue engineering are expected to fuel the market growth. In addition, increasing regulatory approvals for advanced therapy medicinal products have propelled the market growth. The ongoing COVID-19 pandemic created lucrative opportunities for the operating players owing to the urgent need for the development of new therapies against SARS-COV-2. Several initiatives are being implemented in the cell and gene therapy manufacturing industry, including the T-cell therapy space.

Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Furthermore, advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer’s, neurodegenerative diseases, and spinal cord injuries. For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Report Scope of the Regenerative Medicine Market

Key Takeaways:

• By Product, the U.S. Regenerative Medicine market was valued at USD 4.9 Billion in 2021 and expected to witness growth at a CAGR of 15.9% from 2022 to 2030.
• The number of companies engaged in the development of advanced therapies is continuously increasing over the past few years. This is anticipated to increase the competition among companies to create a specific and efficient pipeline
• The therapeutics segment dominated the market in 2021 due to the high usage of primary cell-based therapies along with advances in stem cell and progenitor cell therapies. The implementation of these therapies in dermatological, musculoskeletal, and dental application results in the highest share of this segment
• Stem cell and progenitor cell-based therapies are anticipated to witness rapid growth due to high investments in this research space and an increasing number of stem cell banks
• With the rise in R&D and clinical trials of regenerative medicines, key players are offering several consulting services leading to lucrative growth of the services segment
• The oncology segment is estimated to account for the largest revenue share by 2030 owing to the high prevalence of cancer indications, which drives the demand for better solutions. The presence of a strong pipeline of regenerative medicines for cancer treatment also supplements the segment growth
• North America dominated the market in 2021 and is projected to continue its dominance over the forecast period. A significant number of universities and research organizations investigating various stem cell-based approaches for regenerative apposition in the U.S. propels the region’s growth
• Asia Pacific is projected to witness the fastest CAGR over the forecast period due to the emergence of key players and rapid adoption of cell-based approaches in the healthcare

Full Report is Ready | Quick Buy This Premium Report from Here@ https://www.novaoneadvisor.com/report/checkout/6841

Market Dynamics

Driver: Growing prevalence of chronic diseases, genetic disorders, and cancer

The incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe, over the last few decades. The increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, can be a result of diabetes and obesity, which will require treatments and incur exorbitant medical expenses.

Opportunity: Implementation of the 21st Century Cures Act

The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, to advance regenerative medicine research and medical innovation this new law has been enacted and covers various provisions that may impact the approval and development of several products in the coming years.

Restraint: High cost of cell and gene therapies

Patients suffering from terminal illnesses and serious disorders requires cell and gene therapies which represent a significant scientific and medical advancement. These therapies are helping to transform how diseases are treated and potentially cured. Furthermore, such therapies will eventually enable doctors and medical professionals to infuse genes/cells via injectable means in order to avoid a series of drugs and multiple surgeries in patients. However, despite the fact of these therapies being lifesavers and more effective compared to the traditional treatments, the response in terms of demand for these therapies is less compared to the anticipation. This can be attributed to the high costs of these therapies and difficulty in obtaining reimbursements and coverage for these therapies.

Regional Insight

North America dominated the global market in 2020with a revenue share of more than 45%. This is attributed to the presence of a significant number of key players in the U.S. The availability of advanced technologies and the presence of research institutes that are involved in the development of novel therapeutics are attributive to the high number of clinical trials in this region.

Availability of funds as well as several initiatives by the government & private organizations contributes to the highest revenue flow from the U.S. For instance, the “2020: A New Vision” initiative of the U.S. Department of Health and Human Services recognizes regenerative medicine at the forefront of healthcare.

Asia Pacific is predicted to witness the fastest CAGR over the forecast period owing to the expansion of infrastructure and facilities to accelerate stem cell research in the emerging economies of the region. In Japan, the Ministry of Health, Labor and Welfare approved Regenerative Medicine law in April 2013, which propelled the clinical development of regenerative and cell-based therapies. Similarly, the Chinese government has approved several research activities related to human embryonic stem cells that have encouraged researchers to explore the clinical potential of these cells.

Some of the prominent players in the Regenerative Medicine market include:

• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• Integra Lifesciences Corp.
• Astellas Pharma, Inc.
• Cook Biotech, Inc.
• Bayer AG
• Pfizer, Inc.
• Merck KGaA
• Abbott
• Vericel Corp.
• Novartis AG
• GlaxoSmithKline (GSK)
• Baxter International, Inc.
• Boehringer Ingelheim
• Amgen Inc.
• Cesca Therapeutics, Inc.
• U.S. Stem Cell, Inc.
• Bristol-Myers Squibb
• Eli Lilly and Company
• NuVasive, Inc.
• Organogenesis, Inc.
• MiMedx Group, Inc.
• Takara Bio, Inc.
• Osiris Therapeutics, Inc.
• Corline Biomedical AB

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Regenerative Medicine market

• Product
  • Therapeutics
    • Primary Cell-based Therapeutics
      • Dermatology
      • Musculoskeletal
      • Surgical
      • Dental
      • Others
    • Stem Cell & Progenitor Cell-based Therapeutics
      • Autologous
      • Allogeneic
      • Others
    • Cell-based Immunotherapies
    • Gene Therapies
  • Tools
  • Banks
  • Services
• Therapeutic Category
  • Dermatology
  • Musculoskeletal
  • Immunology & Inflammation
  • Oncology
  • Cardiovascular
  • Ophthalmology
  • Others

Regional Segmentation

• Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
• Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
• North America [United States, Canada, Mexico]
• South America [Brazil, Argentina, Columbia, Chile, Peru]
• Middle East & Africa [GCC, North Africa, South Africa]

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6841

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.